NuWays AG Initiates BUY Rating for NanoRepro AG

NuWays AG has initiated a BUY recommendation for NanoRepro AG with a target price of €4.3 over 12 months. NanoRepro has transitioned from a self-test company to a multi-brand consumer health platform. The company has centralized key functions, enhancing operational efficiency.

ZuhauseTEST, a core asset of NanoRepro, is Germany's widest OTC testing brand, featuring 16 CE-certified products. Since April 2025, it benefits from full IVDR certification, supporting its presence in a market with a 12.4% annual growth rate.

Additionally, NanoRepro's portfolio includes Paedi Protect AG and Deutsche Kosmetikwerke AG, expanding its skincare and active skincare offerings. The Phlas cold plasma device represents a promising advancement in acne treatment, underpinning future growth.

At a market cap of roughly €20 million, investors benefit from potential revenue synergies and undervaluation of key business units. NuWays suggests significant upside potential for NanoRepro.